Trial Profile

An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms VOLFI

13 Jun 2023 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results of pooled analysis assessing prognostic and predictive value of primary tumor location by using data from five studies (FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
10 Feb 2022 This trial has been completed in Germany (End Date: 20 Jan 2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com